Lupus erythematosus-like imiquimod reaction

A diagnostic pitfall

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.

Original languageEnglish (US)
Pages (from-to)346-350
Number of pages5
JournalJournal of Cutaneous Pathology
Volume38
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

imiquimod
Toll-Like Receptor 7
Actinic Keratosis
Skin
Erythema
Cellular Immunity
Dendritic Cells
Monocytes
Histology
Pain
Therapeutics

ASJC Scopus subject areas

  • Dermatology
  • Pathology and Forensic Medicine
  • Histology

Cite this

Lupus erythematosus-like imiquimod reaction : A diagnostic pitfall. / Barr, Keira L.; Konia, Thomas; Fung, Maxwell A.

In: Journal of Cutaneous Pathology, Vol. 38, No. 4, 04.2011, p. 346-350.

Research output: Contribution to journalArticle

@article{a83671c0a92b46dfa4de573ee1adafca,
title = "Lupus erythematosus-like imiquimod reaction: A diagnostic pitfall",
abstract = "Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.",
author = "Barr, {Keira L.} and Thomas Konia and Fung, {Maxwell A}",
year = "2011",
month = "4",
doi = "10.1111/j.1600-0560.2010.01592.x",
language = "English (US)",
volume = "38",
pages = "346--350",
journal = "Journal of Cutaneous Pathology",
issn = "0303-6987",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Lupus erythematosus-like imiquimod reaction

T2 - A diagnostic pitfall

AU - Barr, Keira L.

AU - Konia, Thomas

AU - Fung, Maxwell A

PY - 2011/4

Y1 - 2011/4

N2 - Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.

AB - Imiquimod (AldaraTM), a Toll-like receptor 7 agonist (TLR7), is known for its unique properties of being an immune response modifier and stimulator. Upon topical application, this TLR7 agonist triggers a cell-mediated immune response predominantly expressed by dendritic cells and monocytes. Local skin irritation at the application site involving erythema, pain, crusting and erosions is common and well documented. On the contrary, the specific histopathologic features associated with these treatment site reactions is not. Herein reported is a case where historical omission of imiquimod use for actinic keratosis complicated the histologic interpretation. We highlight a lupus erythematosus-like microscopic pattern and explore histopathologic features that could help in avoiding a diagnostic pitfall, as well as the relationship between TLR activation, cell-mediated immunity and skin histology.

UR - http://www.scopus.com/inward/record.url?scp=79951732489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951732489&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0560.2010.01592.x

DO - 10.1111/j.1600-0560.2010.01592.x

M3 - Article

VL - 38

SP - 346

EP - 350

JO - Journal of Cutaneous Pathology

JF - Journal of Cutaneous Pathology

SN - 0303-6987

IS - 4

ER -